Kornimate/medical-research-clean huggingface dataset:
study of atrn-119 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: the purpose of this study is to assess the safety and effectiveness of atrn-119 through the performance of a phase 1/2a, open-label, safety, pk, and preliminary efficacy study of oral atrn-119 in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * dna damage response (ddr) mutations documented in the past medical record or confirmed during the screening period. * measurable disease defined by recist 1.1. * life expectancy ≥ 3 months. * subject must be capable of oral administration of study medication. exclusion criteria: * patient has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks. * surgical procedure performed within 7 days prior to first scheduled dose of atrn-119. * concomitant treatment with strong inhibitors or inducers of cyp3a4 and cyp2d6. * known human immunodeficiency virus infection (hiv). * subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications. * current or past diagnosis of leukemia within the past 5 years. * prior radiotherapy at the target lesion unless there is evidence of disease progression. * known cns metastases or clinical evidence of cns involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging \[mri\] brain). * history of non-malignant gastronintestinal (gi) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months. * patient has uncontrolled hypertension at time of enrollment. * complete left bundle branch block (lbbb), bifascicular block (right bundle branch block \[rbbb\] with either left anterior hemiblock or left posterior hemiblock). * any clinically significant st segment and/or t-wave abnormalities. * myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.
a pilot trial of remotely-supervised transcranial direct current stimulation (rs-tdcs) to enhance motor learning in progressive multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: this is a randomized, double-blind pilot clinical trial to test a novel treatment approach to rehabilitate fine motor function in individuals living with progressive multiple sclerosis (ms) using anodal transcranial direct current stimulation (tdcs) to augment manual dexterity training. treatment will be delivered to individuals at home using a state-of-the-art remotely supervised tele-rehabilitation protocol, a major advantage for patients with respect to ease of access, feasibility, reinforcement learning and minimal burden of in clinic study visit participation. improvements in fine motor skill will be assessed at each remote session using a novel portable grip device that measures execution and adaptation or learning of fingertip forces during grasp, which is more sensitive than standard measures of hand function.


Eligibility criteria:
inclusion criteria: * definite ms diagnosis, progressive subtype * 9hpt score between -1.0 and -4.0 standard deviations from age-based normative data * score of \< 7.5 or less on the edss (with caregiver proxy required for those with scores of 6.5 or greater)\* * ability to understand the informed consent process and provide consent to participate in the study exclusion criteria: * primary neurologic, psychiatric or other medical disorder other than ms * use of upper extremity botox injection within 3 months * current use of intrathecal baclofen * history of seizure disorder * history of head trauma or medical device in head or neck * clinically significant abnormality on ekg * symbol digit modalities test or sdmt score ≥3.0 sd from published norms * wrat-4 reading level below average (\<85) (estimated general intellectual function) * skin disorder/sensitive near stimulation locations

Keywords: anodal transcranial stimulation (tdcs)
eeg monitoring in children with moyamoya disease

Conditions: EEG With Periodic Abnormalities

Summary: eeg in moyamoya disease in children preoperatively

eeg monitoring in children with moyamoy disease preoperatively for 10 minutes

Eligibility criteria:
inclusion criteria: * moyamoya disease exclusion criteria: * refusal
personality bleaching

Conditions: Personality

Summary: 128 patients between 18 and 76 years who attended the operative dentistry clinic at dental school, universidad de chile, were included in the study. 58 patients were bleaching (experimental group) and 70 patients don't accepted the bleaching procedure (control group) were included in this study and signed a consent form.experimental group patients who agreed to be bleaching were treated with 10% carbamide peroxide (cp) gel (whiteness perfect, fgm) to each subject with verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the neo-ffi personality test form, had 30 minutes to answer it.control group:patients who refused to be bleached were administered the personality test neo-ffi, had 30 minutes to answer it.

data collection neo-ffi data was collected in a microsoft excel data sheet and analyzed by a psychology that was blind to patient's expectations. according to the answers, each scale might get a score between 0 and 50. statistical analysis for comparisons between scales between groups of patients were bleaching and who refused to be bleached mann whitney test was used.for each pair of scales it was determined if any one of them predominated over its counterpart by wilcoxon rank test before and after bleaching . to corroborate the statistical power of this study was calculated post-hoc with the neo-ffi scores values between the comparisons and showed a high statistical power (0.99) by g-power software.

Eligibility criteria:
inclusion criteria: * participants included in this clinical trial were between 18 and 76 years old and had good general and oral health. each subject had at least one central incisor with shade a2 or darker, assessed by comparison with a value-oriented shade guide (vita classical, vita zahnfabrik, bad säckingen, germany) exclusion criteria: * participants that had undergone previous dental bleaching procedures during orthodontic treatment, or those that were pregnant or lactating women and participants with bruxism habits, were not included in the trial. additionally, participants with restorations on the labial surfaces of their anterior teeth and non-carious cervical lesions, veneers or full crowns, with gingival recession, spontaneous tooth pain, internal tooth discoloration, and teeth with endodontic treatment or fluorosis were also excluded from this trial

Keywords: personality bleaching
exploratory study in achievement of improved survival by molecular targeted chemotherapy and liver resection for not optimally resectable colorectal liver metastases

Conditions: Liver Metastasis; Colorectal Cancer

Summary: the correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.

the correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.

Eligibility criteria:
inclusion criteria: * patients who registered the atom trial and signed informed consent prior to initiation of any trial-specific procedure and treatment. exclusion criteria: * none

Keywords: liver only metastasis from kras exon 2 wild type liver only metastasis from ras wild type
enzyme activity of matrix metalloproteinases in the serum of patients with malignant obstructive hyperbilirubinemia before and after ptbd

Conditions: Matrix Metalloproteinase

Summary: the purpose of this study is to detect differences in the enzymatic activity of matrix metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after percutaneous biliary drainage.

this study will be designed as a prospective cohort study involving the collection of peripheral blood samples before and one month after percutaneous biliary drainage for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity). biochemical analyzes are preceded by the entry of data relevant to the research (demographic, anamnestic, clinical and biochemical).

Eligibility criteria:
inclusion criteria: pathological confirmation or imaging data confirming malignant disease causing bile duct obstruction, performance status 0-1 exclusion criteria: terminally ill patients, performance status \>2, hepatic decompensation, severe underlying cardiac or renal diseases and coagulation disorders.

Keywords: biliary drainage, matrix metalloproteinases
does miecc improve outcome in diabetic patients undergoing elective coronary bypass grafting?

Conditions: Acute Kidney Injury

Summary: the aim of this study was to prospectively evaluate mecc compared with conventional extracorporeal circulation of diabetic patients undergoing elective coronary revascularization procedures. the investigators focused on the effects of extracorporeal circulation especially the renal function between both groups.

cardiopulmonary bypass (cpb) is known having a negative influence referring to systemic inflammatory reaction after cardiac surgery which can cause acute kidney injury (aki). miniaturized extracorporeal circulation (mecc) attempts to reduce the adverse effects of conventional extracorporeal circulation bypass. finally, aki after cpb is a significant clinical problem that increasingly complicates the course of hospitalization and clinical outcome.

Eligibility criteria:
inclusion criteria: * diabetes mellitus type 2 * isolated elective coronary revascularization exclusion criteria: * urgent or emergent status * re-operation * preexisting reanimation * preexisting renal transplantation * chronic kidney insufficiency (gfr \< 30 ml/min) * renal cell carcinoma * renal artery stenosis * heart valve disease (middle- and high-grade) * endocarditis * infections (hiv, tbc and all types of hepatitis) * hepatic cirrhosis
synoste nitinail system trial

Conditions: Leg Length Inequality

Summary: synoste nitinail system trial is an international multicenter open label single-arm equivalence study to verify whether the leg-lengthening procedure can be adequately controlled with the sns system as measured with the lengthening control index (lci) at the end of the distraction period.

the synoste nitinail system (sns) is an assembly of an active implantable distraction nail (synoste nitinail), locking screws, accessory instruments for surgery and the home care unit (also external control unit (ecu) or halo). it includes also, a software tool, syndex, that supports setting up the number of lengthening activations needed per day. the sns is intended for lengthening of the femur by distraction osteogenesis. the study will consist of a recruitment period of 3 months and an observation period of roughly 24 months (6 months after explantation). the observation period is split in two parts: the first part contains the most critical treatment phases from implantation surgery of the device through the actual lengthening phase up to the end of the bone healing. the second part contains only two visits: the explantation surgery of the device and a control at 6 months of further follow-up. after the fist part of the trial, a primary analysis of the data including the hypothesis testing will be carried out. after the second part of the trial a follow-up analysis will be done. 16 (max 20) patients will be recruited in finland and turkey.

Eligibility criteria:
inclusion criteria: * indication for femoral lengthening from different etiologies of max. 70 mm at single lengthening * 18 to 65 years regardless of gender * suitable anatomy for sns * able and willing to comply with study procedures exclusion criteria: * other electronic implants * other metallic implants in the affected limb below the osteotomy level * need for magnetic resonance imaging during the study * bmi\>30kg/m2 or weight\>100kg * smoker * known hypersensitivity to co, ni, cr or ti metals * known hypersensitivity to poly-ether-ether-ketone (peek) or ultrahigh molecular weight poly-ethylene (uhmwpe) * open growth plates * malignancy or tumor in bone * osteitis or soft tissue infection * significant existing deficit in range of motion of the adjacent joints * pseudoarthrosis * pregnancy * low psychological compliance (e.g. drug abuse) * simultaneous bilateral lengthening * need for osteotomies at multiple levels

Keywords: distraction osteogenesis bone lengthening leg length discrepancy callotasis intramedullary distraction nail
effect of snps in the bcmo1 enzyme

Conditions: Beta-carotene Bioavailability; Vitamin A Deficiency

Summary: summary: chronic intake of foods low in vitamin a (retinol) and provitamin a forming an unbalanced diet with little variety is common in young individuals in the united kingdom (uk) population and can lead to subclinical micronutrient deficiency. provitamin a sources such as β-carotene are cleaved centrally by the β-carotene 15,15'-monooxygenase (bcmo1) into retinal, the precursor of retinol. however, the amount of β-carotene and retinol produced after ingestion of β-carotene is highly variable between healthy individuals, with approximately 40% of the subjects being classified as low responders. several stable isotope studies have shown a large disparity between the most efficient converters and the most inefficient converters of β-carotene with variations of up to 8-fold. it is possible that differences in β-carotene response may be due to single nucleotide polymorphisms (snps) in genes involved in aspects of β-carotene conversion. previous work has shown that carriers of both, the 379v and 267s+379v bcmo1 variant alleles had a reduced ability to convert β-carotene. more importantly, 44% of the western population have the 379v haplotype. a high percentage of the western population may therefore not be able to achieve adequate vitamin a intake if dietary β-carotene is a major source of their vitamin a intake. this is of particular relevance to vegetarians, to young individuals aged 19-24 years who have lower intakes of preformed retinol than any other age group, and to pregnant women. the aim of this study is to establish whether the maximum recommended dose for β-carotene of 7mg/day by the british expert committee on vitamins and minerals (evm) can overcome the snp effect in the bcmo1 enzyme. hypothesis: the investigators hypothesize that the current maximum recommended intake of 7 mg of β-carotene per day cannot overcome the low convertor phenotype in bcmo1 to fulfill vitamin a requirements in these people.


Eligibility criteria:
inclusion criteria: * healthy individual. * female. * between 18 and 45 years of age. * caucasian. * bmi between 18 and 30 kg/m2. * subject willing and able to give written informed consent. exclusion criteria: * smoking. * diabetes. * gastrointestinal diseases. * renal and hepatic diseases. * hyperlipidaemia. * preformed dietary retinol intake above 60% of reference nutrient intake (rni) values. * recreational drug use. * multi-vitamin consumption. * pregnancy. * menopause. * allergy or sensitivity to study products or ingredients. * blood donation 3 months prior to screening. * participation in other clinical study 4 weeks prior to study start. * suspected inability or unwillingness to comply with study procedures.

Keywords: beta carotene retinol
mobilization with neuromuscular electrical stimulation in critical care patients

Conditions: Muscular Atrophy

Summary: neuromuscular electrical stimulation in pectoral muscles (fibres of the pectoralis major muscle bilaterally) and rectus abdominis muscles (bilaterally) preserves / decreases the loss of muscle mass.

introduction: neuromuscular electrical stimulation (nmes) has recently began to be used as an early treatment method for intensive care unit (icu) patients on invasive mechanical ventilation (imv) to compensate for or reduce muscle mass losses and muscular atrophy. objective: to evaluate the effects of early mobilization with neuromuscular electrical stimulation in critical care patients on invasive mechanical ventilation. methods: randomized clinical trial to be conducted in the icu at the hospital de clínicas of porto alegre, rs, brazil, with two groups, one intervention group (conventional physiotherapy and nmes) and one placebo group (conventional physiotherapy and placebo nmes). patients on mechanical ventilation who meet the inclusion criteria will be recruited and the intervention will be administered using a 4-channel ibramed® neurodyn functional electrical stimulation (fes) machine, every day for thirty minutes until extubation or death. outcomes will be muscle thickness of pectoral and abdominal muscles and diaphragm excursion measured with ultrasound, before intervention, on the seventh day of intervention and soon after extubation. additionally, blood lactate and heart rate variability will be assessed. statistical analysis will be conducted using the statistical package for the social sciences (spss) 20.0 and the significance level will be p\<0.05.

Eligibility criteria:
inclusion criteria: this will be a randomized clinical trial recruiting patients of both sexes aged ≥ 18 years, no more than 15 days after admission to the intensive care unit at the hospital de clínicas de porto alegre, after transfer from the emergency department or wards and put on invasive mechanical ventilation for at least 24 hours - exclusion criteria: * exclusion criteria will include neuromuscular diseases causing motor deficits, such as strokes, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis and guillain barré syndrome. patients will also be excluded in the event of extubation less than 48 hours after enrolment on the study; complications during the protocol, such as pneumothorax, reintubation or delayed weaning (3 failed spontaneous ventilation tests); body mass index (bmi) \> 35 kg/m2; pacemaker use, history of epilepsy; or if a patient has undergone an operation involving abdominal or pectoral incisions.

Keywords: electrical stimulation intensive care unit muscular atrophy
decisions of young women with breast cancer regarding fertility preservation before cancer treatment and family building after treatment

Conditions: Fertility Preservation; Breast Cancer

Summary: this study will help the researchers learn more about factors that affect the decisions about fertility preservation and family building made by young women with breast cancer.


Eligibility criteria:
inclusion criteria: * breast cancer, stage 0-iii * female * 18-45 years of age at time of diagnosis * patients that completed their primary breast cancer treatment (surgery, chemotherapy, radiation therapy). patients can still be on endocrine therapy, trastuzumab and/or pertuzumab therapy. * received education and counseling by msk fertility nurse specialist before beginning cancer treatment from 2009 through 2018 exclusion criteria: * unable to read english

Keywords: quality of life web-based questionnaire 18-461
mechanistic study on the diagnosis of esophageal cancer lymph node metastasis using spectral ct, multimodal mri, fapi pet-ct, pathology, and ai evaluation system

Conditions: Esophageal Cancer

Summary: the objective of this study is to address the urgent issues in the diagnosis of lymph node metastasis in esophageal cancer. by employing multimodal mri, spectral ct imaging and fapi pet-cttechniques, the study will correlate lymph node images with postoperative pathology results. additionally, ai technology will be applied to learn from multimodal imaging data, enabling comprehensive analysis and evaluation of lymph node metastasis. using a large volume of clinical and imaging data, a predictive model will be established to provide individualized lymph node metastasis risk assessments for each esophageal cancer patient. this will, in turn, offer robust support for personalized treatment strategies in esophageal cancer.


Eligibility criteria:
inclusion criteria: 1. consecutive patients with pathological diagnosis of esophageal cancer. 2. patients underwent radical esophagectomy and lymph node dissection, with preoperative multimodal mri, spectral ct and fapi pet-ct ; patients underwent neoadjuvant therapy followed by radical surgery, with preoperative multimodal mri, spectral ct and fapi pet-ctboth before and after neoadjuvant therapy. 3. no history of malignant tumors or cancer-related treatments. 4. complete postoperative pathological data, allowing for a one-to-one comparison of preoperative lymph node imaging and postoperative histopathology for evaluation. exclusion criteria: 1. contraindications for mri, spectral ct or fapi pet-ct. 2. patients who refuse to participate in this study.
german tavi-register

Conditions: Aortic Valve Stenosis; Aortic Valve Insufficiency

Summary: the tavi - register is a germany-wide scientific elevation in which data about the aortic valve treatment and the therapeutic consequences are documented.

documentation of all consecutive patients of the participating centers with significant aortic stenosis, undergoing one of the following therapies: 1. percutaneous transfemoral aortic valve replacement 2. percutaneous aortic valve replacement transapical 3. percutaneous aortic valve replacement transaortic 4. aortic valve balloon valvuloplasty 5. surgical aortic valve replacement 6. conservative treatment * documentation of the indications, procedural results and clinical short-and long-term results of the above therapies * documentation of operational risk and quality of life * documentation of the technical implementation of the procedure and success of the intervention and of hospital reinterventions * documentation of hospital mortality, nonfatal major complications (stroke, tia, myocardial infarction, dialysis, vascular complications, bleeding, neuropsychological status) * documentation of discharge medication and the length of hospital stay * documentation of the serious long-term complications, including mortality, stroke, tia, myocardial infarction, dialysis, the reintervention and quality of life and of drug therapy within 30 days, 1 year, 3 years and 5 years.

Eligibility criteria:
inclusion criteria: patients with aortic stenosis (degree iii) who received one of the following therapies: * transapical operative aortic valve implantation * operative aortic valve implantation * percutaneous aortic valve implantation * balloon valvuloplasty exclusion criteria: * missing signed informed consent

Keywords: aortic valve stenosis aortic valve insufficiency transapical aortic valve implantation aortic valve replacement percutaneous aortic valve replacement aortic valve valvuloplasty